Ballentine Partners’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $505K | Sell |
961
-49
| -5% | -$25.7K | 0.01% | 480 |
|
|
2025
Q1 | $641K | Buy |
1,010
+93
| +10% | +$59K | 0.01% | 374 |
|
|
2024
Q4 | $653K | Sell |
917
-145
| -14% | -$103K | 0.01% | 368 |
|
|
2024
Q3 | $1.12M | Buy |
1,062
+50
| +5% | +$52.6K | 0.02% | 262 |
|
|
2024
Q2 | $1.06M | Sell |
1,012
-28
| -3% | -$29.4K | 0.02% | 246 |
|
|
2024
Q1 | $1M | Buy |
1,040
+285
| +38% | +$274K | 0.02% | 248 |
|
|
2023
Q4 | $663K | Sell |
755
-241
| -24% | -$212K | 0.01% | 304 |
|
|
2023
Q3 | $820K | Buy |
996
+283
| +40% | +$233K | 0.02% | 221 |
|
|
2023
Q2 | $512K | Sell |
713
-404
| -36% | -$290K | 0.01% | 311 |
|
|
2023
Q1 | $918K | Buy |
1,117
+342
| +44% | +$281K | 0.02% | 209 |
|
|
2022
Q4 | $559K | Buy |
775
+194
| +33% | +$140K | 0.02% | 257 |
|
|
2022
Q3 | $401K | Buy |
581
+233
| +67% | +$161K | 0.01% | 280 |
|
|
2022
Q2 | $206K | Sell |
348
-30
| -8% | -$17.8K | 0.01% | 398 |
|
|
2022
Q1 | $264K | Buy |
+378
| New | +$264K | 0.01% | 379 |
|
|
2016
Q3 | – | Sell |
-638
| Closed | -$222K | – | 230 |
|
|
2016
Q2 | $222K | Buy |
638
+13
| +2% | +$4.52K | 0.02% | 189 |
|
|
2016
Q1 | $225K | Buy |
+625
| New | +$225K | 0.02% | 182 |
|